Share This!

Raymond “Ramiro” Sanchez Jr., MD, Presented with the Albert Nelson Marquis Lifetime Achievement Award by Marquis Who’s Who

Dr. Sanchez has been endorsed by Marquis Who’s Who as a leader in the fields of psychiatry and pharmaceuticals

PRINCETON, NJ, November 15, 2017, Marquis Who’s Who, the world’s premier publisher of biographical profiles, is proud to present Raymond “Ramiro” Sanchez Jr., MD, with the Albert Nelson Marquis Lifetime Achievement Award. An accomplished listee, Dr. Sanchez celebrates many years’ experience in his professional network, and has been noted for achievements, leadership qualities, and the credentials and successes he has accrued in his field. As in all Marquis Who’s Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Dr. Sanchez is a trained psychiatrist who is a senior vice president of global clinical development at Otsuka Pharmaceutical Development and Commercialization (OPDC) in Princeton, NJ. The company, which was originally founded in 1921 and has a second U.S. location in Rockville, MD, has two core businesses – pharmaceutical and nutraceutical. The pharmaceutical business develops and markets products for the diagnosis and treatment of disease in the central nervous system, oncology, gastroenterology, ophthalmology, and cardiovascular. The nutraceutical business is dedicated to maintaining and improving health through the use of foods and beverages that provide extra health benefits in addition to their basic nutritional value. With more than 20 years of experience in academic, medical, and pharmaceutical fields, Dr. Sanchez’s extensive knowledge in business has made him a key player in the success of the organization.

Prior to serving as senior vice president at Otsuka, Dr. Sanchez spent three years as vice president of global clinical development for the company and three years as senior director of global clinical development. He also worked for Bristol-Myers Squibb as a group medical director and medical lead in neurosciences in Paris, France, from 2005 to 2007, as well as a group medical director for neuroscience global clinical research from 2004 to 2005 and medical director for neuroscience global clinical research from 2000 to 2004. He also worked for Purdue Pharma, L.P., for two years as an associate medical director for the division of medical research.

Serving on many boards and committees during his tenure, Dr. Sanchez has been serving on the executive board for the Journal of Sleep Disorders and Sleep Studies since 2017 as well as executive chairman of the International Society for Central Nervous System Drug Development. Since 2016, he has also been serving on the executive advisory council for the National Alliance of Mental Illness. He is also a founding member of the Central Nervous System (CNS) Summit since 2012 and trustee for the Connecticut Mental Health Center Foundation board of trustees at Yale University School of Medicine since 2000. He also maintains membership with organizations such as the American Medical Association, the American Psychiatric Association, and the American Society of Clinical Psychopharmacology, and is an oversees fellow of the Royal Society of Medicine in England.

Dr. Sanchez first earned a Bachelor of Arts in Psychology with distinction and departmental honors from the Weinberg College of Arts and Sciences at Northwestern University. He then completed a post-baccalaureate research appointment at Harvard University Medical School, Sleep Disorders Medicine, between 1984 and 1986, before earning an MD at Northwestern University’s Feinberg School of Medicine in 1994. Dr. Sanchez then completed his internship in medicine, neurology, and psychiatry at Yale-New Haven Hospital as well as residency in psychiatry at Yale University School of Medicine.

Throughout his journey, Dr. Sanchez has authored dozens of articles across many professional journals such as the Journal of Clinical Psychopharmacology, The International Journal of Neuropsychopharmacology, the Journal of Clinical Psychiatry, the American Journal of Psychiatry, and The Journal of Child and Adolescent Psychopharmacology. He has also authored countless abstracts and presentations between 2003 and 2016, most recently including “Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study, Randomized Withdrawal Study,” which was presented at the American College of Neuropsychopharmacology’s 55th annual meeting in Hollywood, FL, in December 2016.

Since 1983, Dr. Sanchez has earned several grants and awards, including a 2016 Leadership Award by the International Society for CNS Drug Development, 2015 Otsuka President’s Award for Rexulti Dual-Indicator Approval, and a 2010 Otsuka President’s Award for Abilify Maintena Program Leadership. Furthermore, Dr. Sanchez has been the recipient of a 2006 Grant Award for Outstanding Performance and Leadership and 2004 STAR Award, both by Bristol-Myers Squibb.

In recognition of outstanding contributions to his profession and the Marquis Who’s Who community, Ramiro Sanchez Jr., MD, has been featured on the Albert Nelson Marquis Lifetime Achievement website. Please visit for more information about this honor.